Business Development DNA Genomics Marketing 
pharmaphorum
OCTOBER 12, 2022
David Del Bourgo (CEO and co-founder, Whitelab Genomics) has always been passionate about introducing disruptive, innovative technologies to markets. We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says.
pharmaphorum
OCTOBER 1, 2021
Shares in DNA sequencing specialist Oxford Nanopore rocketed after the company made its debut on the London Stock Exchange yesterday, rising nearly 50% to propel its valuation up towards the £5 billion ($6.7 The post Oxford Nanopore makes stellar debut on UK stock market appeared first on. billion) mark.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
JUNE 5, 2023
New approaches to partnering In this event in the Biotech track, Clive Cookson, Science Editor at the Financial Times, interviewed John McDonald, Corporate Vice President, Global R&D Business Development, Novo Nordisk. The panel was moderated by Alexander Nuyken, Head Life Sciences Markets Europe, Middle East & Africa, JLL.
The Pharma Data
JUNE 7, 2023
In addition to mRNA, Acuitas LNP can be used to deliver a range of different nucleic acid therapeutics including small interfering RNA (siRNA), antisense oligonucleotides and DNA. “Accessing state-of-the-art LNP technology through this collaboration will add momentum to our gene editing efforts for the benefit of patients.”
Drug Discovery World
APRIL 17, 2024
JMB: There’s no doubt that it’s been a tough environment to raise funds, and the market has only worsened in 2023. It had been known for decades that TFs, which orchestrate a cell’s gene expression programs, bind to DNA and proteins. DS: You raised $100 million in a Series B financing round in 2022.
pharmaphorum
MARCH 8, 2022
After a few years, I decided I wanted to move into the commercial side of the business, so I completed an MBA and went on to hold various positions in Corporate Business Development, Life Science and Healthcare. I have been general manager for Merck Healthcare UK & Ireland since 2020.
Drug Discovery World
APRIL 29, 2024
Dr Andrew Lewis, Chief Scientific Officer; Kieron Hall, Chief Marketing Officer; and Eric Bironneau, Chief Business Officer, Quotient Sciences: Lewis has held various scientific leadership positions at Quotient and was previously Director of Novel Drug Delivery Technologies at Ipsen.
Expert insights. Personalized for you.
105 
Let's personalize your content